prikaz prve stranice dokumenta The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE
  Preuzmi
PDF 405 KB
Znanstveni rad - Izvorni znanstveni rad
The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE
Croatian Medical Journal, 62 (2021), 6; 542-552. https://doi.org/10.3325/cmj.2021.62.542
Beck, Eduard; Mandalia, Sundhiya; Yfantopoulos, Platonas; Jones, Christopher; Bremner, Stephen; Whetham, Jennifer; Benković, Ivana; Zekan, Šime; Begovac, Josip

Citiranost:
,
Citirajte ovaj rad

Beck, E., Mandalia, S., Yfantopoulos, P., Jones, C., Bremner, S., Whetham, J. ... Begovac, J. (2021). The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE. Croatian Medical Journal, 62. (6), 542-552. doi: 10.3325/cmj.2021.62.542

Beck, Eduard, et al. "The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE." Croatian Medical Journal, vol. 62, br. 6, 2021, str. 542-552. https://doi.org/10.3325/cmj.2021.62.542

Beck, Eduard, Sundhiya Mandalia, Platonas Yfantopoulos, Christopher Jones, Stephen Bremner, Jennifer Whetham, Ivana Benković, Šime Zekan i Josip Begovac. "The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE." Croatian Medical Journal 62, br. 6 (2021): 542-552. https://doi.org/10.3325/cmj.2021.62.542

Beck, E., et al. (2021) 'The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE', Croatian Medical Journal, 62(6), str. 542-552. doi: 10.3325/cmj.2021.62.542

Beck E, Mandalia S, Yfantopoulos P, Jones C, Bremner S, Whetham J, i sur.. The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE. Croatian Medical Journal [Internet]. 31.12.2021. [pristupljeno 16.03.2025.];62(6):542-552. doi: 10.3325/cmj.2021.62.542

E. Beck, et al., "The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE", Croatian Medical Journal, vol. 62, br. 6, str. 542-552, Prosinac 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:479513. [Citirano: 16.03.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:479513
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)The cost of care for people living with stable HIV in Croatia and the efficiency of EmERGE
AutorEduard Beck
AutorSundhiya Mandalia
AutorPlatonas Yfantopoulos
AutorChristopher Jones
AutorStephen Bremner
AutorJennifer Whetham
AutorIvana Benković
AutorŠime Zekan
AutorJosip Begovac
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INFEKTOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (engleski)
Aim: To estimate the cost-effectiveness of the EmERGE Pathway of Care for medically stable people living with HIV (PLHIV) at the University Hospital for Infectious Diseases (UHID), Zagreb. The Pathway includes a mobile application enabling individuals to communicate with their caregivers. ----- Methods: This study involving 293 participants collected data on the use of HIV outpatient services one year before and after EmERGE implementation. In departments supporting HIV outpatients, a... Više micro-costing exercise was performed to calculate unit costs. These were combined with mean use of HIV services per patient year (MPPY) to estimate average annual costs. Primary outcomes were CD4 count, viral load, and secondary outcomes were patient activation, PAM13; and quality of life, PROQOL-HIV. Information on out-of-pocket expenditures was also collected. ----- Results: Outpatient visits decreased by 17%, from 4.0 (95% CI 3.8-4.3) to 3.3 MPPY (95% CI 3.1-3.5). Tests, including CD4 count, decreased, all contributing to a 33% reduction of annual costs: 7139 HRK (95% CI 6766-7528) to 4781 HRK (95% CI 4504-5072). Annual costs including anti-retroviral drugs (ARVs) decreased by 5%: 43101 HRK (95% CI 42728-43,490) to 40 743 HRK (95% CI 40466-41,034). ARVs remain the main cost driver in stable PLHIV. Primary and secondary outcomes did not change substantially between periods. ----- Conclusion: EmERGE Pathway was a cost-saving intervention associated with changes in management, and a reduction in outpatient visits, tests, and costs. ARV costs dominated costs. Future efficiencies are possible if EmERGE is introduced to other PLHIV across the UHID and if ARV prices are reduced. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 62, br. 6, str. 542-552
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2021.62.542
URN:NBNurn:nbn:hr:105:479513
Datum objave publikacije2021-12-31
URL dokumentahttps://pubmed.ncbi.nlm.nih.gov/34981686/
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2022-01-17 09:42:08
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.